ClinicalTrials.gg
CompletedNCT01289028Updated Jan 2, 2017Results posted

Efficacy of Nilotinib in Adult Patients With Gastrointestinal Stromal Tumors Resistant to Imatinib and Sunitinib.

A Phase 3 interventional study of Nilotinib in Gastrointestinal Stromal Tumors, sponsored by Novartis Pharmaceuticals. Completed at 19 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-01-02.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
125
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 14 studies testing nilotinib in Gastrointestinal Stromal Tumors — none open to participants now, none under way, none of them phase 3. nilotinib · Gastrointestinal Stromal Tumors.

Enrollment
3rd of 14
125 · median 35
Started
2008
with 5 others
Phase 3
4 of 14
none open now
Registered
12th of 14
by date
Lead sponsor
12 of 14
Novartis Pharmaceuticals

Among the 14 studies testing nilotinib in Gastrointestinal Stromal Tumors, this one is the 3rd largest by enrollment, is one of 6 that started in 2008, is one of 4 in phase 3, and was the 12th registered.

Gastrointestinal Stromal Tumors

343 studies on the registry are indexed under Gastrointestinal Stromal Tumors; 61 are open to participants now.

Browse Gastrointestinal Stromal Tumors studies →

Open to participants now

None of the 14 studies testing nilotinib in Gastrointestinal Stromal Tumors is open now. The open studies under Gastrointestinal Stromal Tumors, anywhere →

About nilotinib

nilotinib: first FDA approval 2007 (TASIGNA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 49 Gastrointestinal Stromal Tumors studies recruiting now, 38 (78%) set no upper age limit and 4 (8%) stop at 75 or younger; 6 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies testing nilotinib in Gastrointestinal Stromal Tumors as a file.
02

Study summary

This study will evaluate the preliminary efficacy of nilotinib in pretreated patients (Imatinib, Sunitinib) with unresectable or metastatic gastrointestinal stromal tumors.

03

Conditions studied

  • Gastrointestinal Stromal Tumors

Keywords

  • GIST
  • Imatinib
  • Sunitinib
  • Gastrointestinal
  • Stromal
  • Tumors
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed diagnosis of GIST that is unresectable and/or and therefore not amenable to surgery or combined modality with curative intent.
  • Radiologically confirmed disease progression during imatinib therapy at a dose of at least 400 mg daily and/or radiologically confirmed disease progression during sunitinib therapy OR documented intolerance to imatinib and/or sunitinib. (Patients with prior additional treatment of GIST prior to study entry can be included.)
  • At least one measurable site of disease on CT/MRI as defined by criteria.

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with nilotinib.
  • Treatment with any cytotoxic and/or cytotoxic drug ≤ 4 weeks (6 weeks for nitrosurea or mitomycin C) prior to Visit 1.
  • Prior or concomitant requiring active treatment other than GIST with the exception of previous or concomitant basal cell skin cancer, previous cervical carcinoma in situ.
  • Impaired cardiac function at visit 1
  • Patients with severe and/or uncontrolled concurrent medical disease that in the opinion of the investigator could cause unacceptable safety risks or compromise compliance with the protocol e.g. impairment of gastrointestinal (GI) function, or GI disease that may significantly alter the absorption of the study drugs, uncontrolled diabetes.

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
125 participants (actual)

Study arms

  • Experimental
    Nilotinib

    nilotinib 400 mg twice daily (bid).

    Drug: Nilotinib

Interventions

06

What researchers measure

Primary outcomes

  1. Percent of Patients Achieving Stable Disease (SD)

    Neither sufficient shrinkage to qualify for Partial Response nor sufficient increase to qualify for Progression Disease, taking as reference the smallest sum of the longest diameter since the treatment started.

    Time frame: During the first 4 months

  2. Percent of Patients Achieving Partial Response (PR)

    The primary efficacy variable was defined as the proportion of patients with a best overall response of CR by Week 16/Month 4 based on local assessment according to RECIST (Version 1.0). This is an at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter.

    Time frame: during the first 4 months

  3. Percent of Patients Achieving Complete Response (CR)

    Complete response (CR) is the Disappearance of all target lesions.

    Time frame: during the first 4 months

Secondary outcomes

  1. Analysis of Time to Overall Response (CR or PR) According to RECIST Using Kaplan-Meier Method for ITT Population

    Complete Response (CR): Disappearance of all target lesions. and Partial Response (PR): At least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter.

    Time frame: 24 weeks and 52 weeks

  2. Time to Overall Response (CR or PR): Per Protocol Population

    Complete Response (CR): Disappearance of all target lesions, and Partial Response (PR): At least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter.

    Time frame: 24 weeks and 52 weeks

  3. Time to Tumor Progression

    Time to tumor progression defined as the time from start of treatment to observed tumor progression (censoring for death without progression) as stated in the original protocol was not evaluated as stated in section 9.8.3 of the clinical study report.

    Time frame: during the first 4 months

  4. Duration of Overall Response

    The best overall response is the best response recorded from the start of the treatment until disease progression/recurrence

    Time frame: during 12 months

  5. Overall Survival, Number of Events Related to Progression of the Disease

    The OS rate could not be calculated due to the high number of censored cases. Number of censored, n (%) 108 (86.4). Only available data is number of events. OS was defined as the time from first study drug administration to death from any cause. If a patient was not known to have died, survival was censored at date of last contact.

    Time frame: during 12 months

  6. Progression Free Survival (PFS) of the Patients Who Were Included Due to an Intolerability of a Prior Treatment.

    Progression-free survival (PFS) is defined as the time from first study drug administration to objective tumor progression or death from any cause. If a patient has not had an event, PFS is censored at the date of last adequate tumor assessment.

    Time frame: during 12 months

07

Results

Posted Nov 1, 2016

Participant flow

Participant flow — Overall Study
MilestoneNilotinib
Started125
Completed42
Not completed83
Withdrew: Progressive disease49
Withdrew: Adverse event14
Withdrew: Withdrawal by subject6
Withdrew: Death4
Withdrew: Lack of efficacy2
Withdrew: No longer required2
Withdrew: Lost to follow-up2
Withdrew: New cancer therapy2
Withdrew: Abnormal lab value1
Withdrew: Missing reason for discon1

Outcome measures

PrimaryPercent of Patients Achieving Stable Disease (SD)

Neither sufficient shrinkage to qualify for Partial Response nor sufficient increase to qualify for Progression Disease, taking as reference the smallest sum of the longest diameter since the treatment started.

Time frame:
During the first 4 months
Reported as:
Number · % participants
Percent of Patients Achieving Stable Disease (SD)
% participantsNilotinib
Percent of Patients Achieving Stable Disease (SD)48.8
PrimaryPercent of Patients Achieving Partial Response (PR)

The primary efficacy variable was defined as the proportion of patients with a best overall response of CR by Week 16/Month 4 based on local assessment according to RECIST (Version 1.0). This is an at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter.

Time frame:
during the first 4 months
Reported as:
Number · percentage of participants
Percent of Patients Achieving Partial Response (PR)
percentage of participantsNilotinib
Percent of Patients Achieving Partial Response (PR)0
PrimaryPercent of Patients Achieving Complete Response (CR)

Complete response (CR) is the Disappearance of all target lesions.

Time frame:
during the first 4 months
Reported as:
Number · percentage of participants
Percent of Patients Achieving Complete Response (CR)
percentage of participantsNilotinib
Percent of Patients Achieving Complete Response (CR)0
SecondaryAnalysis of Time to Overall Response (CR or PR) According to RECIST Using Kaplan-Meier Method for ITT Population

Complete Response (CR): Disappearance of all target lesions. and Partial Response (PR): At least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter.

Time frame:
24 weeks and 52 weeks
Reported as:
Number · percentage of participants
Analysis of Time to Overall Response (CR or PR) According to RECIST Using Kaplan-Meier Method for ITT Population
percentage of participantsNilotinib
24 weeks92.0
52 weeks92.0
SecondaryTime to Overall Response (CR or PR): Per Protocol Population

Complete Response (CR): Disappearance of all target lesions, and Partial Response (PR): At least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter.

Time frame:
24 weeks and 52 weeks
Reported as:
Number · percentage of participants
Time to Overall Response (CR or PR): Per Protocol Population
percentage of participantsNilotinib
24 weeks91.2
52 weeks91.2
SecondaryTime to Tumor Progression

Time to tumor progression defined as the time from start of treatment to observed tumor progression (censoring for death without progression) as stated in the original protocol was not evaluated as stated in section 9.8.3 of the clinical study report.

Time frame:
during the first 4 months

No measurements were reported for this outcome.

SecondaryDuration of Overall Response

The best overall response is the best response recorded from the start of the treatment until disease progression/recurrence

Time frame:
during 12 months
Reported as:
Median · days
Duration of Overall Response
daysNilotinib
Duration of Overall Response1331 (366 to NA)
SecondaryOverall Survival, Number of Events Related to Progression of the Disease

The OS rate could not be calculated due to the high number of censored cases. Number of censored, n (%) 108 (86.4). Only available data is number of events. OS was defined as the time from first study drug administration to death from any cause. If a patient was not known to have died, survival was censored at date of last contact.

Time frame:
during 12 months
Reported as:
Number · events
Overall Survival, Number of Events Related to Progression of the Disease
eventsNilotinib
Overall Survival, Number of Events Related to Progression of the Disease17
SecondaryProgression Free Survival (PFS) of the Patients Who Were Included Due to an Intolerability of a Prior Treatment.

Progression-free survival (PFS) is defined as the time from first study drug administration to objective tumor progression or death from any cause. If a patient has not had an event, PFS is censored at the date of last adequate tumor assessment.

Time frame:
during 12 months
Reported as:
Median · days
Progression Free Survival (PFS) of the Patients Who Were Included Due to an Intolerability of a Prior Treatment.
daysNilotinib
Progression Free Survival (PFS) of the Patients Who Were Included Due to an Intolerability of a Prior Treatment.110 (64 to 118)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
All Patients—60/125 (48%)107/125 (85.6%)
Most frequent serious events
Showing 10 of 79
Most frequent serious events
EventAll Patients
Abdominal painGastrointestinal disorders7/125
AnaemiaBlood and lymphatic system disorders6/125
Disease progressionGeneral disorders6/125
VomitingGastrointestinal disorders5/125
PyrexiaGeneral disorders5/125
ConstipationGastrointestinal disorders3/125
FatigueGeneral disorders3/125
General physical health deteriorationGeneral disorders3/125
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)3/125
Tumour painNeoplasms benign, malignant and unspecified (incl cysts and polyps)3/125
Most frequent other events
Showing 10 of 33
Most frequent other events
EventAll Patients
FatigueGeneral disorders44/125
ConstipationGastrointestinal disorders32/125
Abdominal painGastrointestinal disorders28/125
NauseaGastrointestinal disorders28/125
VomitingGastrointestinal disorders21/125
PruritusSkin and subcutaneous tissue disorders21/125
PyrexiaGeneral disorders19/125
DiarrhoeaGastrointestinal disorders18/125
Decreased appetiteMetabolism and nutrition disorders18/125
Oedema peripheralGeneral disorders17/125

Baseline characteristics

Age, Continuous
Age, Continuous(years)Nilotinib
Mean60 ± 12.1
Gender
Gender(Participants)Nilotinib
Female46
Male79
08

Study locations

19 sites
  • Novartis Investigative Site
    Bad Saarow, 155226, Germany
  • Novartis Investigative Site
    Dresden, 01307, Germany
  • Novartis Investigative Site
    Duesseldorf, 40479, Germany
  • Novartis Investigative Site
    Essen, 45122, Germany
  • Novartis Investigative Site
    Frankfurt, 60488, Germany
  • Novartis Investigative Site
    Freiburg, 79106, Germany
  • Novartis Investigative Site
    Halle/'Saale, 06120, Germany
  • Novartis Investigative Site
    Hannover, 30625, Germany
  • Novartis Investigative Site
    Mannheim, 68167, Germany
  • Novartis Investigative Site
    Muenchen, 81377, Germany
  • Novartis Investigative Site
    Muenchen, 81675, Germany
  • Novartis Investigative Site
    Ulm, 89081, Germany
  • Novartis Investigative Site
    Bologna, BO 40138, Italy
  • Novartis Investigative Site
    Genova, GE 16132, Italy
  • Novartis Investigative Site
    Taormina, ME 98039, Italy
  • Novartis Investigative Site
    Milano, MI 20133, Italy
  • Novartis Investigative Site
    Padova, PD 35100, Italy
  • Novartis Investigative Site
    Aviano, PN 33081, Italy
  • Novartis Investigative Site
    Torino, TO 10153, Italy
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2008, a primary completion of Jul 2014 and a completion of Jul 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2016, 2 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2011
First posted
Feb 3, 2011
Start
Nov 2008
Primary completionActual
Jul 2014
CompletionActual
Jul 2014
Results first posted
Nov 1, 2016
Last update
Jan 2, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 2, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01289028
Responsible party
Sponsor
First posted
Feb 3, 2011
Start date
Nov 2008
Primary completion
Jul 2014
Completion
Jul 2014
Results posted
Nov 1, 2016
Last update
Jan 2, 2017

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nilotinib

Start the discussion